KRRO VS IGMS Stock Comparison

Performance

KRRO
100/100

KRRO returned 192.66% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

IGMS
10/100

IGMS returned -81.00% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Earnings

KRRO
100/100

KRRO has missed earnings 0 times in the last 20 quarters.

IGMS
67/100

IGMS has missed earnings 3 times in the last 20 quarters.

Volatility

KRRO
100/100

KRRO has had a higher than average amount of volatility over the last 12 months giving it a score of 100 of 100.

IGMS
43/100

IGMS has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

Sentiment

KRRO

"Sentiment" not found for KRRO

IGMS
68/100

IGMS had a bullish sentiment score of 68.02% across Twitter and StockTwits over the last 12 months. It had an average of 4.12 posts, 0.42 comments, and 0.47 likes per day.

Technicals

KRRO

"Technicals" not found for KRRO

IGMS
50/100

IGMS receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Profit

KRRO

"Profit" not found for KRRO

IGMS
10/100

Out of the last 20 quarters, IGMS has had 0 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

Korro Bio, Inc. Common Stock Summary

Nasdaq / KRRO

Healthcare

Biotechnology

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

IGM Biosciences, Inc. Common Stock Summary

Nasdaq / IGMS

Healthcare

Biotechnology

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Power up your portfolio